Kingella kingae is a new pathogen mostly associated with infections in children. Given our strong background and technical expertise, our team strives to offer Kingella kingae infections vaccine and therapeutics development services tailored to your needs.
Introduction to Kingella Kingae Infection
Kingella kingae is a bacterial infection that primarily targets young children. It was first deemed as a non malignant bacteria but currently is considered to be quite dangerous. K. Kingae can cause septicemia, endocarditis, osteoarticular infections and even severe septic arthritis and osteomyelitis.
Fig.1 The outer membrane tbpA and hpuB proteins of Kingella kingae. (Mashraqi M. M., et al., 2023)
Vaccine Development for Kingella Kingae Infection
Chimeric Vaccines
Chimeric vaccines which have multi epitopes are prepared to get a better immunogenic response from an individual and such vaccines are currently leading in the field of vaccinology and vaccine design. The epitope predictions of B and T-cell epitopes from p T-BAR, for example, a bioinformatics tool aids in mining conserved protein domains from outer membrane proteins of k kingae, such as α-barrel TonB-dependent receptor.
Subunit Vaccines
Using Kingella kingae hpuB and tbpA proteins, subunit vaccines have been developed by incorporating other specific components of the pathogen. Since these epitopes are thought to be greatly immunogenic & conserved among all strains, there is the possibility of creating a highly effective vaccine.
Therapeutics Development for Kingella Kingae Infection
The therapeutics for infections caused by Kingella kingae is primarily dependent on antibiotic therapy. There exists a range of antibiotic therapies for vast majority of the strains including oral and subcutaneous antibiotics recommended for children with fever, but these strains are becoming an increasingly common issue. The invention of β-lactamase strains , however, has made it necessary to work on better strategies to monitor and contain resistance to antibiotics.
There have been instances when rifampin was suggested that could act as a prophylactic antibacterial medicine during the outbreak to control the further spread. Given the mechanism of action of rifampin against Kingella kingae and its high concentrations in upper respiratory tract mucosa and its salivary secretion, it can be considered that rifampin can act as an eradicative agent for the invasive pathogen as well as any other bacteria associated with it.
Interestingly, the use of prophylactic medications has been shown to be effective in managing Kingella kingae infections, but still poses a significant challenge. Our company has a solution for this too as we have a concrete plan to develop medications to treat the Kingella kingae infection. For further insights, kindly follow the link below.
Our Services
Our organization offers an extensive array of services aimed at developing kingella kingae vaccines and therapeutics. Our highly skilled experts, equipped with advanced knowledge in microbiology, immunology and drug development technologies specialize in accelerating the pace of your research and development work for Kingella kingae.
Infectious Disease Models
- Genotype-Phenotype Correlation Models
- Septic Arthritis and Osteomyelitis Models
- Intraperitoneal Inoculation Models
- Endocarditis Models
- Age-Dependent Susceptibility Models
We offer preclinical research services that may extend to in vitro and in vivo studies with regards to the safety, immunogenicity, and efficacy of our vaccine and/ or therapy candidates. Engaging in these services also includes molecular dynamics simulation as a means to determine the candidates' stability and conformational dynamics. If this is something you feel like you might require, feel free to contact us and we will happily assist you with further information related to our services. Or, you can directly request a detailed quotation.
Reference
- Mashraqi, Mutaib M., et al. "Chimeric vaccine design against the conserved TonB-dependent receptor-like β-barrel domain from the outer membrane tbpA and hpuB proteins of Kingella kingae ATCC 23330." Frontiers in Molecular Biosciences 10 (2023): 1258834.
All of our services and products are intended for preclinical research use
only and cannot be used to diagnose, treat or manage patients.
